GlassScriptPhysician profile
Paolo Soriano
NPI 1932581022
$4,208.61
in general payments reported to CMS, 2019-2025
42 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.45 · 2020: $75.99 · 2021: $165 · 2022: $170 · 2023: $475 · 2024: $1,586 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,343.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $139.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $663.71 | 2022-2025 | |
| Daiichi Sankyo INC. | $297.81 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $277.83 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $263.82 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $176.05 | 2023-2025 | |
| Epizyme, INC. | $168.54 | 2021-2022 | |
| Abbvie INC. | $145.45 | 2023-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $145.35 | 2023-2025 | Imfinzi, Lynparza |
| Janssen Biotech, INC. | $142.56 | 2022-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $132.08 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $130.79 | 2019-2025 | Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $125.00 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Incyte Corporation | $120.67 | 2020-2025 | Jakafi |
| Genentech USA, INC. | $112.93 | 2021-2025 | Venclexta, Itovebi, Phesgo |
| Genzyme Corporation | $108.98 | 2024-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paolo Soriano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.